title: Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway.
abstract: BACKGROUND
  Danqi Pill (DQP), which contains Chinese herbs Salvia miltiorrhiza Bunge and Panax notoginseng, is widely used in the treatment of myocardial ischemia (MI) in China. Its regulatory effects on MI-associated lipid metabolism disorders haven't been comprehensively studied so far. We aimed to systematically investigate the regulatory mechanism of DQP on myocardial ischemia-induced lipid metabolism disorders.
  
  
  METHODS
  Myocardial ischemia rat model was induced by left anterior descending coronary artery ligation. The rat models were divided into three groups: model group with administration of normal saline, study group with administration of DanQi aqueous solution (1.5 mg/kg) and positive-control group with administration of pravastatin aqueous solution (1.2 mg/kg). In addition, another sham-operated group was set as negative control. At 28 days after treatment, cardiac function and degree of lipid metabolism disorders in rats of different groups were measured.
  
  
  RESULTS
  Plasma lipid disorders were induced by myocardial ischemia, with manifestation of up-regulation of triglyceride (TG), low density lipoprotein (LDL), Apolipoprotein B (Apo-B) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). DQP could down-regulate the levels of TG, LDL, Apo-B and HMGCR. The Lipid transport pathway, fatty acids transport protein (FATP) and Carnitine palmitoyltransferase I (CPTI) were down-regulated in model group. DQP could improve plasma lipid metabolism by up-regulating this lipid transport pathway. The transcription factors peroxisome proliferator-activated receptor α (PPARα) and retinoid X receptors (RXRs), which regulate lipid metabolism, were also up-regulated by DQP. Furthermore, DQP was able to improve heart function and up-regulate ejection fraction (EF) by increasing the cardiac diastolic volume.
  
  
  CONCLUSIONS
  Our study reveals that DQP would be an ideal alternative drug for the treatment of dyslipidemia which is induced by myocardial ischemia.
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. doctor_wangyong@163.com.
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. 34451574@qq.com.
authors.forename: Chun
authors.initials: C
authors.lastname: Li
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. wangqybucm@163.com.
authors.forename: Qiyan
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. tianjiaoshi1988@sina.cn.
authors.forename: Tianjiao
authors.initials: T
authors.lastname: Shi
authors.affiliation: Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. wangjingbucm@163.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. chbucm@163.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. yanwubucm@163.com.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. hanjingbucm@sina.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Han
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. shuzhenguo@sina.cn.
authors.forename: Shuzhen
authors.initials: S
authors.lastname: Guo
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. yybucm@163.com.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Beijing University of Chinese Medicine, Beijing, 100029, China. wangwei26960@126.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
mesh_terms: D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000097:blood; D002681:China; D003324:Coronary Artery Disease / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D050612:Fatty Acid Transport Proteins / Q000097:blood; D006321:Heart / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects*; D052439:Lipid Metabolism Disorders / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D017202:Myocardial Ischemia / Q000150:complications / Q000378:metabolism; D053723:Panax notoginseng; D008517:Phytotherapy; D017207:Rats, Sprague-Dawley; D027561:Salvia miltiorrhiza; D014157:Transcription Factors / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation
chemical_list: D004365:Drugs, Chinese Herbal; D050612:Fatty Acid Transport Proteins; D008055:Lipids; D014157:Transcription Factors; D014280:Triglycerides; D002334:Carnitine O-Palmitoyltransferase